Metronomic Outpatient-Based Chemotherapy with 5′-DFUR and Low-Dose Cisplatin for Conventional Platinum-Based Chemotherapy-Resistant Advanced Urothelial Cancer
Clinical medicine. Oncology · 2007
DOI: 10.4137/cmo.s304 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical medicine. Oncology, 2007. Verfasst von Tomohiko Hara und 7 weiteren Autor:innen. Die Arbeit nennt 29 Literaturangaben.
Themen: Onkologische Pflege
Abstract (Originalsprache)
Background
Metronomic chemotherapy is aimed at lessening the adverse effects of treatment while rendering cancer cells cytostatic. The oral 5-fluorouracil prodrug “5′-DFUR” has been shown to inhibit angiogenesis and is regarded as a good candidate agent for metronomic chemotherapy. Moreover, cisplatin and 5′-DFUR have been shown to synergistic cytotoxic effects.
Methods
We evaluated the safety and efficacy of metronomic chemotherapy using daily oral 5′-DFUR at the dose of 600 mg/day and biweekly cisplatin infusion at the dose of 20 mg/person in 23 patients with urothelial cancer resistant to conventional platinum-based chemotherapy.
Results
Twenty-three patients were enrolled between August 2000 and December 2004. The median survival time after the initiation of metronomic chemotherapy was 15.2 months. The 1-year, 2-year and 3-year survival rates were 55.1%, 45.1% and 5.9%, respectively. Grade 3 fatigue was observed as severe toxicity in one patient. No cases showed nephrotoxicity and adverse effects necessitating medical intervention.
Conclusions
Although a large-scale prospective study would be necessary before the therapy is established as a standard, our metronomic chemotherapy regimen appears to be a potentially useful palliative treatment alternative for patients with advanced urothelial cancer resistant to conventional platinum-based chemotherapy. Abbreviations M-VAC: methotrexate, vinblastine, doxorubicin, and cisplatin; GC: gemcitabine and carboplatin; 5′-DFUR: 5′-deoxy-5-fluorouridine; 5-FU: 5-fluorouracil; CDDP: cisplatin; TCC: transitional cell carcinoma; ECOG: Eastern Cooperative Oncology Group; PS: performance status; UICC: Union International Contre le Cancer; WHO: World Health Organization; NCI-CTC: National Cancer Institute Common Toxicity Criteria; CI: confidence interval; PR: partial response; NC: no change; PD: progressive disease; TP: thymidine phosphorylase; AUC: areas under the curve.
Zitieren
APA
Hara, T., Yoshihiro, S., Ito, H., Nagao, K., Ohmi, C., Sakano, S., Matsuyama, H., & Naito, K. (2007). Metronomic Outpatient-Based Chemotherapy with 5′-DFUR and Low-Dose Cisplatin for Conventional Platinum-Based Chemotherapy-Resistant Advanced Urothelial Cancer. Clinical medicine. Oncology. https://doi.org/10.4137/cmo.s304
Vancouver
Hara T, Yoshihiro S, Ito H, Nagao K, Ohmi C, Sakano S, et al. Metronomic Outpatient-Based Chemotherapy with 5′-DFUR and Low-Dose Cisplatin for Conventional Platinum-Based Chemotherapy-Resistant Advanced Urothelial Cancer. Clinical medicine. Oncology. 2007. doi:10.4137/cmo.s304
BibTeX
@article{Hara2007,
author = {Hara, Tomohiko and Yoshihiro, Satoru and Ito, Hideaki and Nagao, Kazuhiro and Ohmi, Chietaka and Sakano, Shigeru and Matsuyama, Hideyasu and Naito, Katsusuke},
title = {Metronomic Outpatient-Based Chemotherapy with 5′-DFUR and Low-Dose Cisplatin for Conventional Platinum-Based Chemotherapy-Resistant Advanced Urothelial Cancer},
journal = {Clinical medicine. Oncology},
year = {2007},
doi = {10.4137/cmo.s304}
}
EUVIMED